We will connect you to the doctor responsible for this trial and help you get more information.
Locations near you
Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Full eligibility criteria for NCT01320696
Ages eligible for Study
18 Years to 49 Years
Genders eligible for Study
Accepts Healthy Volunteers
Subject is 18 to 49 years of age, inclusive, on the day of screening
Subject has an understanding of the study and its procedures, agrees to its provisions, and gives written informed consent prior to study entry
Subject is generally healthy, as determined by the investigator's clinical judgement through collection of medical history and performance of a physical examination
Subject is physically and mentally capable of participating in the study as determined by the investigator
Subject agrees to keep a daily record of symptoms for the duration of the study
If female of childbearing potential, subject presents with a negative urine pregnancy test within 24 hours prior to first vaccination and agrees to employ adequate birth control measures for the duration of the study. For the purposes of this study at least one of the following types of US Food and Drug Administration (FDA) approved birth control measures shall be applied through completion of the Day 181 study visit:
Hormonal types of birth control (such as implants or birth control pills) or an intrauterine device
A barrier type of birth control measure (i.e. condoms, diaphragms, cervical caps, etc.)
Subject has a history of exposure to H9N2 influenza virus or a history of vaccination with an H9N2 influenza vaccine
Subject is at potential occupational risk of contracting H9N2 influenza infection
(e.g. poultry workers)
Subject currently suffers from or has a history of a significant (requiring hospitalization or change in intervention in past 6 months)neurological, cardiovascular, pulmonary (including asthma), hepatic, rheumatic, autoimmune, hematological, metabolic or renal disorder such as but not limited to: multiple sclerosis, lupus, Guillain-Barre syndrome as determined by the investigator
Subject has a body temperature of >= 100.4 degrees Fahrenheit (>= 38.0 degrees Celsius) on the day of vaccination, by oral measurement. [NOTE: Subjects meeting this exclusion criterion may be rescheduled for vaccination and study entry at a later date provided: 1) body temperature measured orally has decreased to < 100.4 degrees Fahrenheit (< 38.0 degrees Celsius); 2) all other inclusion/exclusion criteria are met; 3) the rescheduled date is no more than 14 days past the initial screening assessments and date; and 4) the study site is still enrolling subjects and randomization is not closed]
Subject has a Body Mass Index (BMI) >= 35
Subject has hypertension at screening that is graded as greater than Stage 1 (defined as a systolic pressure > 159 or diastolic pressure > 99 while seated and at rest
(measurement shall be repeated twice before subject is excluded)
Subject has clinically significant abnormal laboratory values at screening as determined by the investigator
Subject tests positive for Human Immunodeficiency Virus (HIV), Hepatitis B surface Antigen (HBsAgs) or Hepatitis C Virus (HCV)
Subject has any medically diagnosed or suspected immune deficient condition based on medical history and physical examination as determined by the investigator
Subject has an immune compromising condition or disease, or is currently undergoing a form of treatment or was undergoing a form of treatment within 30 days prior to study entry that can be expected to influence immune response. Such treatment includes, but is not limited to, systemic or high dose inhaled (> 800 μg/day of beclomethasone dipropionate or equivalent) corticosteroids, radiation treatment or other immunosuppressive or cytotoxic drugs (use of inhaled and nasal steroids will be permitted)
Subject has a history of severe (required immediate medical life threatening treatment and/or hospitalization) allergic reactions or anaphylaxis as determined by the investigator
Subject has a rash, dermatologic condition or tattoos which may interfere with injection site reaction rating as determined by the investigator
Subject has received any blood products (e.g. blood transfusion or immunoglobulins) within 90 days prior to study entry
Subject has donated one or more units of blood (approximately 450 mL) or plasma within 30 days prior to study entry
Subject has received any live vaccine within 4 weeks or an inactivated vaccine or a subunit vaccine within 2 weeks prior to vaccination in this study
Subject has a functional or surgical asplenia
Subject has a positive urine drug screen (unless the subject is currently prescribed the drug detected by a licensed health care provider and the continued administration of the drug would not otherwise exclude the subject from participation)
Subject has a known or suspected problem with alcohol or drug abuse as determined by the investigator
Subject is currently enrolled or has participated in another clinical study involving an investigational products (IP) or device within 30 days prior to study enrollment or is scheduled to participate in another clinical study involving an IP or device during the course of this study
Subject is a member of the team conducting this study or is in a dependent relationship with one of the study team members. Dependent relationships include close relatives (i.e. children, partner/spouse, siblings, parents) as well as employees of the investigator or site personnel conducting the study
If female, subject is pregnant or lactating at the time of study enrollment
Any condition that in the opinion of the investigator would interfere with evaluation of the vaccine or interpretation of study results
All locations for NCT01320696
United States (5)
Huntsville, Alabama, United States, 35802
Melbourne, Florida, United States, 32935
Peoria, Illinois, United States, 61602
South Bend, Indiana, United States, 46601
Rockville, Maryland, United States, 20850
View full eligibility
Tris trial is registered with FDA with number: NCT01320696. The sponsor of the trial is Ology Bioservices and it is looking for 275 volunteers for the current phase.
Official trial title: A Randomized, Double Blind, Multi-center, Phase 1/2 Study to Assess Safety and Immunogenicity of Five Dose Levels of a Reverse Genetic (RG) Reassortant H9N2 Pandemic Influenza Vaccine in Healthy Subjects Aged 18 to 49 Years
1What's a trial
4Get in touch
What's a trial
Not sure you're well informed about clinical trials? Learn more about their benefits, risks and other important details.
Enter your details like condition, age, gender and other preferences and we will show you a list of all relevant clinical trials.
Review the summary of the selected clinical trial and all the locations near you in order to see if it's of interest to you.
Get in touch
You've found an interesting trial? We'll need a bit more information about you so we can connect you to the doctor in charge.
Some people want to consult their doctor before considering participation in a clinical trial. This is absolutely normal as your doctor should know your medical history and should be able to advise you. If you want you can easily share the information for this trial with your doctor by clicking on the button below.